Jack W. Schuler Buys 100,000 Biodesix Shares At $10.02, Below His August Prices

The investor used personal funds for the living trust's purchase and reported approximately 22.3% beneficial ownership.

Share
Jack W. Schuler Buys 100,000 Biodesix Shares At $10.02, Below His August Prices

Investor Jack W. Schuler bought 100,000 shares of Biodesix, which sells blood-based lung-disease tests and testing services for developers, through his living trust Tuesday at an average $10.02. His amended SEC ownership filing Thursday put that price below the $24.47 average he paid on August 12.

Buying Below His August Prices

Schuler funded the open-market purchase with personal money. His principal business is investing in securities, and his Biodesix ownership disclosures began on November 9, 2020; his previous amendment was dated January 27, 2026.

The living trust's August purchases comprised 13,900 shares on August 10 at an average $24.25, 13,700 on August 11 at $24.01 and 15,000 on August 12 at $24.47.

BDSX shares traded at $10.18 in Thursday trading, as of 9:43 a.m. ET, below each of those August averages. Biodesix's market value was $112 million at that Thursday reading.

The Trusts Behind The Stake

Schuler reported beneficial ownership of 2,476,545 shares, or approximately 22.3%. That position includes shares held by trusts for which he serves as sole trustee, along with rights to receive 20,735 shares within 60 days.

The Jack W. Schuler Living Trust held 655,810 shares, representing approximately 5.9%. The Jack W. Schuler 2026 GRAT, a grantor retained annuity trust, held 1,800,000 shares, or approximately 16.2%.

The trust holdings changed earlier in the year. On March 25, 2026, the Jack W. Schuler 2025 GRAT transferred 750,000 shares to the living trust without additional payment and ceased holding Biodesix shares. The living trust transferred 1,800,000 shares to the 2026 GRAT on April 1, 2026, also without additional payment.

Schuler's rights to receive shares consist of options covering 4,156 shares and vested stock awards covering 16,579. His ownership calculation includes those rights alongside the company's 11,088,511 shares outstanding as of October 30.

Lung Testing Drives The Business

Biodesix's Lung Diagnostic Testing business generated $79.2 million in revenue in 2025 from 62,600 tests delivered. Its five tests include two for assessing cancer risk in lung nodules and three for guiding treatment following a lung-cancer diagnosis.

Development Services contributed $9.3 million, bringing estimated total revenue to $88.5 million in 2025. That business provides testing and consulting for biopharmaceutical, life sciences and diagnostics companies and has served over 65 industry clients and academic research partners.

Third-party payers, including Medicare and private insurers, pay for most of Biodesix's tests.

Sources

More on Biodesix

All Biodesix (BDSX) coverage →